Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.
作者信息
Douxfils Jonathan, Boretti Emma, Beaudart Charlotte, Dogné Jean-Michel
机构信息
Research Unit in Clinical Pharmacology and Toxicology, Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, University of Namur, Rue de Bruxelles, 61, 5000, Namur, Belgium.
QUALIblood s.a., Namur, Belgium.
出版信息
Adv Ther. 2025 Aug;42(8):4089-4091. doi: 10.1007/s12325-025-03242-3. Epub 2025 Jun 4.
Abstract
摘要
相似文献
1
Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.致编辑的信：关于非索奈坦治疗绝经引起的中重度血管舒缩症状的安全性：三项随机3期研究的汇总分析
Adv Ther. 2025 Aug;42(8):4089-4091. doi: 10.1007/s12325-025-03242-3. Epub 2025 Jun 4.
2
3
Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.系统评价和网络荟萃分析比较非激素疗法 fezolinetant 与激素和非激素疗法治疗绝经相关血管舒缩症状的疗效。
Menopause. 2024 Jan 1;31(1):68-76. doi: 10.1097/GME.0000000000002281. Epub 2023 Nov 27.
4
Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy.非索利那新对不适合激素治疗的绝经后女性血管舒缩症状的影响。
Curr Med Res Opin. 2025 Feb;41(2):375-384. doi: 10.1080/03007995.2025.2470752. Epub 2025 Mar 5.
5
Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis.非甾体选择性神经激肽 3 受体拮抗剂（Fezolinetant）治疗与绝经相关的血管舒缩症状：一项荟萃分析。
Climacteric. 2024 Jun;27(3):245-254. doi: 10.1080/13697137.2024.2334083. Epub 2024 Apr 15.
6
A profile of safety and efficacy of fezolinetant for the treatment of menopausal vasomotor symptoms.非佐利坦治疗绝经后血管舒缩症状的安全性和有效性概况。
Expert Rev Clin Pharmacol. 2025 Apr 21:1-12. doi: 10.1080/17512433.2025.2495951.
7
Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.非唑啉坦和依林扎坦治疗绝经后女性血管舒缩症状的疗效与安全性：一项系统评价和荟萃分析。
Maturitas. 2025 Apr;195:108220. doi: 10.1016/j.maturitas.2025.108220. Epub 2025 Feb 22.
8
Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis.非甾体类选择性雌激素受体调节剂费洛司腾特治疗与绝经相关血管舒缩症状的疗效和安全性：一项荟萃分析。
Obstet Gynecol. 2024 Mar 1;143(3):393-402. doi: 10.1097/AOG.0000000000005508. Epub 2024 Jan 16.
9
Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: a comprehensive systematic review and meta-analysis of randomized controlled trials.非唑啉坦治疗绝经后女性血管舒缩症状的疗效和安全性：随机对照试验的综合系统评价和荟萃分析
Proc (Bayl Univ Med Cent). 2025 Jun 17;38(4):535-546. doi: 10.1080/08998280.2025.2491894. eCollection 2025.
10
Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment.非唑奈坦在肝肾功能损害女性中的药代动力学和安全性
J Clin Pharmacol. 2025 Jul 10. doi: 10.1002/jcph.70070.
本文引用的文献
1
Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.非索利那新治疗绝经引起的中度至重度血管舒缩症状的安全性：三项随机3期研究的汇总分析
Adv Ther. 2025 Feb;42(2):1147-1164. doi: 10.1007/s12325-024-03073-8. Epub 2024 Dec 30.
2
Totality of evidence refutes neoplasm risk with fezolinetant - Authors' reply.全部证据反驳了非佐利坦与肿瘤风险的关联——作者回复。
Lancet. 2024 May 18;403(10440):1988. doi: 10.1016/S0140-6736(24)00708-6.
3
Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant.神经激肽3受体拮抗剂非佐利坦导致肿瘤的风险。
Lancet. 2023 Nov 4;402(10413):1623-1625. doi: 10.1016/S0140-6736(23)01634-3. Epub 2023 Oct 18.
4
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.神经激肽-1受体拮抗剂阿瑞匹坦——一种治疗血液系统恶性肿瘤的新药：聚焦急性髓系白血病
J Clin Med. 2020 Jun 1;9(6):1659. doi: 10.3390/jcm9061659.
5
Controversial Role of Kisspeptins/KiSS-1R Signaling System in Tumor Development.亲吻素/ KiSS-1R信号系统在肿瘤发展中的争议性作用
Front Endocrinol (Lausanne). 2018 Apr 30;9:192. doi: 10.3389/fendo.2018.00192. eCollection 2018.
6
Role of Neurokinin 3 Receptor Signaling in Oral Squamous Cell Carcinoma.神经激肽3受体信号传导在口腔鳞状细胞癌中的作用
Anticancer Res. 2017 Nov;37(11):6119-6123. doi: 10.21873/anticanres.12060.
7
The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.NK-1 受体在人类黑色素瘤中表达，并参与 NK-1 受体拮抗剂阿瑞匹坦对黑色素瘤细胞系的抗肿瘤作用。
Lab Invest. 2010 Aug;90(8):1259-69. doi: 10.1038/labinvest.2010.92. Epub 2010 May 10.
8
The KISS1 metastasis suppressor: a good night kiss for disseminated cancer cells.KISS1 肿瘤转移抑制因子：给播散的癌细胞一个晚安之吻。
Eur J Cancer. 2010 May;46(7):1283-9. doi: 10.1016/j.ejca.2010.02.023. Epub 2010 Mar 19.
Zotero 插件